Compare Bio Protocol (BIO) vs Brevis (BREV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio Protocol vs Brevis — how do they compare? Bio Protocol trades at Rp438.28 (market cap Rp1T, Rp164,61M 24h volume), while Brevis trades at Rp1,209 (market cap Rp303,05M, Rp168,03M 24h volume). The key difference: Bio Protocol is far larger — about 3299.8× Brevis's market cap, and Bio Protocol's circulating supply is 2,3B / 3,3B BIO (69%) versus 250M / 1B BREV (25%) for Brevis. Which is the better fit depends on your goals — on Pluang, investors hold Bio Protocol for 18 Days and Brevis for 8 Days on average.
| BIO | BREV | |
|---|---|---|
Market Cap | Rp1T | Rp303,05M |
Volume (24h) | Rp164,61M | Rp168,03M |
Circulating Supply | 2,3B / 3,3B BIO (69%) | 250M / 1B BREV (25%) |
Typical Hold Time | 18 Days | 8 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio Protocol (BIO) trades at Rp438.8 with a market cap of Rp996.68M, showing neutral technical signals overall. The token is currently testing the pivot point at Rp440, with immediate support at Rp430 and resistance at Rp454. With 69% of max supply in circulation and an average hold time of 18 days, the token exhibits moderate liquidity. Recent technical indicators show mixed signals with bearish moving averages but neutral oscillators.
Outlook remains neutral with key opportunities in potential breakout above Rp454 resistance. Major risks include low market cap vulnerability to volatility and limited fundamental developments. Investors should monitor trading volume patterns and broader crypto market sentiment for directional cues.
Brevis (BREV) is trading at Rp1,215.88 with a market cap of Rp304.38 million, showing a bearish technical signal as moving averages indicate strong selling pressure while oscillators remain neutral. The current price sits just below the pivot point of Rp1,219, with immediate support at Rp1,203 and resistance at Rp1,237. No recent protocol updates or ecosystem news are available, and the token has a low circulation rate of 25% with a max supply of 1 million tokens.
Overall outlook is cautious due to bearish technicals and limited liquidity. Key opportunities include potential rebounds from oversold RSI levels, but major risks involve low trading volume, high volatility, and lack of recent development activity, making it susceptible to price swings.
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Bio Protocol
BIO Protocol enables global communities of scientists, patients, and investors to collectively fund, develop, and co-own new drugs and therapeutics through its network of Biotech Decentralized Autonomous Organizations (BioDAOs). The protocol's innovative approach addresses critical gaps in traditional scientific funding, particularly in areas such as rare diseases, longevity research, and emerging health challenges.
Read more on BIO →About Brevis
Brevis is a verifiable computing platform that enables scalable, trustless computation across blockchain, data, and AI systems. It allows complex programs and data queries to run off-chain and be verified on-chain using zero-knowledge proofs, delivering significantly lower costs and latency while preserving security and trustlessness.
Read more on BREV →
